Treatment for up to six months with Batten-1 — Theranexus’ novel therapy for juvenile Batten disease — reduced nerve cell death and stabilized patients’ motor symptoms. That’s according to preliminary results from an ongoing Phase 1/2 clinical trial testing the experimental therapy. The results will be presented at the…
News
A mini pig model could be an effective way to examine brain changes to track disease progression in late infantile Batten disease, a study suggests. In addition, measuring changes in the size of specific brain regions may help identify response to potential treatments, researchers note. “Miniswine present a…
From sharing stories on social media — using hashtags like #BattenDay2023 and #BattenAdvocatesForACure — to wearing something orange this June 9 to participating in a 5K fundraising challenge, supporters globally are poised to mark this year’s International Batten Disease Awareness Day. Observed annually, the June 9 Awareness Day calls attention…
Gene therapy was able to reduce the signs and symptoms of late infantile Batten disease in a mouse model carrying a common disease-causing mutation, a study shows. These findings support Regenxbio’s ongoing gene therapy program, which includes RGX-181, currently being tested as part of a single-patient study…
Changes in the levels of certain metabolites in the brain among people with juvenile Batten disease, also called CLN3 disease, are significantly associated with multiple measures of disease severity, a study showed. Age accounted for many of these metabolite changes. Still, the levels of some brain metabolites — the…
In rare cases, people with juvenile Batten disease may go years or even decades without developing seizures after the onset of vision problems, a new study highlights. Findings suggest that diagnostic delays are common for this rare form of the disease, so researchers urge clinicians to consider it as…
The U.S. Food and Drug Administration (FDA) has cleared the design of a pivotal Phase 3 trial to test Theranexus’ investigational therapy Batten-1 in children and adolescents with juvenile Batten disease. This was the result of a mid-April meeting between the FDA’s Division of Rare Diseases and Medical…
Mutations in genes associated with Batten disease can result in a wide range of clinical manifestations, from whole-body symptoms typical of Batten forms to isolated eye disease, according to a study describing the cases of 11 patients. Clinical variability was seen even among patients carrying the same mutations in…
The Batten Disease Support and Research Association (BDSRA) is challenging people to walk, run, or bike a virtual 5K anytime from now through June 9 as part of International Batten Disease Awareness Day, an annual effort to raise awareness about the disease. People can register to participate…
A lack of the CLN3 protein — the underlying cause of juvenile Batten disease — impairs the function of stress granules (SGs), which are formed to promote cell survival under stressful conditions, according to a cell-based study. CLN3-deficient cells also had lower metabolic rates and were impaired in their…
Recent Posts
- FDA clears late infantile Batten disease gene therapy for testing
- Giving thanks for every milestone as a CLN2 Batten disease parent
- Brain abnormalities can vary by age, sex in juvenile Batten
- How Batten disease parents can drive change through advocacy
- How we celebrate Halloween with medically complex children
- Signs of early brain disruption prompt timely CLN3 gene therapy
- Changing seasons brings precious moments of beauty
- Biotech companies partner on Batten disease gene therapy
- No days off: Living in the fire as a rare disease parent
- Personalized gene therapy benefits twins with juvenile Batten disease